Evidence map›Paper›PMID 39684731›Full record

ArticleInternational journal of molecular sciences2024

The Detection of Toxic Amyloid-β Fibril Fragments Through a Surface Plasmon Resonance Immunoassay.

Marten Beeg, Beatrice Rocutto, Elisabetta Battocchio, Letizia Dacomo, Alessandro Corbelli, Fabio Fiordaliso, Claudia Balducci, Marco Gobbi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marten BeegLaboratory of Pharmacodynamics and Pharmacokinetics, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.ORCID 0000-0001-7201-6704
Beatrice RocuttoLaboratory of Pharmacodynamics and Pharmacokinetics, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.
Elisabetta BattocchioLaboratory of Pharmacodynamics and Pharmacokinetics, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.
Letizia DacomoLaboratory of Biology of Neurodegenerative Disorders, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.
Alessandro CorbelliLaboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.
Fabio FiordalisoLaboratory of Molecular Biology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.ORCID 0000-0002-0172-4030
Claudia BalducciLaboratory of Biology of Neurodegenerative Disorders, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.
Marco GobbiLaboratory of Pharmacodynamics and Pharmacokinetics, Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy.ORCID 0000-0003-1014-6225

Funding

European Union Horizon 2020 research and innovation programme under Grant Agreement No. 964934
6 · The paper itself

Abstract

Amyloid-β1-42 (Aβ42) forms highly stable and insoluble fibrillar structures, representing the principal components of the amyloid plaques present in the brain of Alzheimer's disease (AD) patients. The involvement of Aβ42 in AD-associated neurodegeneration has also been demonstrated, in particular for smaller and soluble aggregates (oligomers). Based on these findings and on genetic evidence, Aβ42 aggregates are considered key players in the pathogenesis of AD and targets for novel therapies. Different approaches are currently used to detect the various aggregation states of Aβ peptide, including spectrophotometric methods, imaging techniques, and immunoassays, but all of these have specific limitations. To overcome them, we have recently exploited the peculiar properties of surface plasmon resonance (SPR) to develop an immunoassay capable of selectively detecting monomers and oligomers, discriminating them also from bigger fibrils in a mixture of different aggregated species, without any manipulation of the solution. In the present study, we extended these previous studies, showing that the SPR-based immunoassay makes it possible to unveil the fibril fragmentation induced mechanically, a result difficult to be conveniently and reliably assessed with other approaches. Moreover, we show that SPR-recognized fibril fragments are more toxic than the larger fibrillar structures, suggesting the relevance of the proposed SPR-based immunoassay.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesSurface Plasmon ResonanceAmyloidHumansImmunoassayPeptide FragmentsAmyloidAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsAlzheimer’s disease (AD)Amyloid-β (Aβ)Aβ fibril fragmentationimmunoassayneurotoxicitysurface plasmon resonance (SPR)

Identifiers

PMID39684731
PMCPMC11640973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.